Travere Therapeutics, Inc.
TVTX
$18.33
$0.703.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 33.17% | -136.36% | 17.78% | -57.60% | -36.99% |
| Total Depreciation and Amortization | 27.43% | -2.06% | -5.50% | 49.24% | 50.32% |
| Total Amortization of Deferred Charges | 0.41% | -- | -- | -- | 5.92% |
| Total Other Non-Cash Items | 138.84% | 103.61% | 571.99% | -48.55% | -81.51% |
| Change in Net Operating Assets | 4.22% | -37.65% | -819.98% | 86.02% | 265.76% |
| Cash from Operations | 49.31% | 28.12% | 41.93% | -46.71% | -28.98% |
| Capital Expenditure | -87.25% | 100.00% | -2,633.33% | -- | 2,243.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -356.95% | -65.40% | 221.83% | 388.11% | 52.02% |
| Cash from Investing | -373.80% | -65.40% | 221.47% | 383.21% | 53.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,000.41% | 278.15% | -57.15% | -- | 704.05% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 28.83% | 33.12% | 33.04% | -102.23% | -1,085.47% |
| Cash from Financing | 112,092.74% | 107.26% | -65.49% | -100.24% | -77.50% |
| Foreign Exchange rate Adjustments | -178.31% | 351.67% | -232.93% | -134.55% | 7.89% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 125.71% | -94.39% | 87.89% | -114.97% | 3.99% |